Vaccination against SARS‐CoV‐2 and psoriasis: the three things every dermatologist should know

Abstract

6 Melanoma patients with unresectable or metastatic disease always require systemic therapy. Patients with active malignant diseases are at increased risk for a severe course of COVID-19 and thus need to be informed to strictly adhere to recommended safety and hygiene procedures (Table Patients requiring targeted therapy, the combination of encorafenib and binimetinib (if available), should be considered over other BRAF and MEK inhibitors (lower rate of pyrexia).